Diego Braguglia
President at Edimer Pharmaceuticals, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
George Fazio | M | 64 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 4 years |
Lars van der Veen | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 7 years |
Catherine Pickering | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Barthélemy Helg | M | 58 |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | 14 years |
Martijn Cox | M | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 18 years |
Fredericus Colen | M | 71 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 1 years |
Djordje Filipovic | M | - |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Adriano Aguzzi | M | - |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Matthew Hua | M | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 12 years |
Cyrill Osterwalder | M | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 6 years |
Benedikt Luhmann | M | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 7 years |
Laurent Massuyeau | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Oleg Svanidze | M | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | - |
Vanessa Malier | F | 51 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | - |
Roel Bulthuis | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 4 years |
Eliane Schutte | F | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 6 years |
Andrea Pfeifer | M | 66 |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Hakan Goker | M | 49 |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Clemens A. van Blitterswijk | M | 67 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | - |
Daniel Gutenberg | M | 58 |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 21 years |
Alain Nicod | M | 64 |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 22 years |
Arnd Kaltofen-Ehmann | M | 64 |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 23 years |
Christian C. Wenger | M | 60 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | 10 years |
Bénédict G. F. Hentsch | M | 76 |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Gerald D. Cagle | M | 79 |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Thomas D. Szucs | M | 64 |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | - |
Joanna Horobin | M | 69 |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 4 years |
Jordi Ahnert | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michel Darnaud | M | 74 |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | - |
Zoltán Czigler | M | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 3 years |
Holger Heims | M | 62 |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 4 years |
Joe Mächler | M | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 3 years |
Monika Krüsi Schädle | M | 62 |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 2 years |
Michelle de Piante Vicin | F | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 2 years |
Boris Warnack | M | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | - |
Frank Lehmann | M | - |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | 8 years |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 36 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Diego Braguglia
- Personal Network